Somatomedin A levels in patients with Cushing's disease

1981 ◽  
Vol 97 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Marja Thorén ◽  
Kerstin Hall ◽  
Tiit Rähn
Keyword(s):  
Direct Effect ◽  
Cushing’S Disease ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Significant Rise ◽  
Radioreceptor Assay ◽  
Cushing's Disease ◽  
Stereotactic Radiation ◽  
Retarding Effect ◽  
Selective Impairment

Abstract. The serum levels of immunoreactive somatomedin A (SMA) in 23 patients with Cushing's disease, aged 6–61 years, were within the range of healthy subjects for their ages. No correlation was found between SMA and the excretion of cortisol. After im administration of hGH (8 IU = 4 mg) daily for 3 days there was a significant rise in SMA, both determined by radioimmunoassay and radioreceptor assay. Thus no impairment was found in the GH-dependent SMA levels or the ability of hGH to generate somatomedin, which indicates that the growth retarding effect of cortisol is most likely due to a direct effect on the tissue. After treatment with stereotactic radiation to the hypophysis there was a significant decrease in cortisol excretion without any change in SMA levels, indicating the possibility to achieve a selective impairment of the ACTH-cortisol axis.

Pituitary Cushing's disease without adenoma

1980 ◽  
Vol 94 (3) ◽  
pp. 297-303 ◽  
Author(s):  
Adrian M. Schnall ◽  
Kalman Kovacs ◽  
Jerald S. Brodkey ◽  
Olof H. Pearson
Keyword(s):  
Pituitary Adenoma ◽  
Cushing’S Disease ◽  
Pituitary Adenomas ◽  
Great Majority ◽  
Serum Levels ◽  
Cushing's Disease ◽  
Serial Sections ◽  
Cell Hyperplasia ◽  
Biochemical Remission ◽  
Lower Limits

Abstract. Recent reports of patients with Cushing's disease who have been explored via the transsphenoidal route indicate that the great majority has pituitary adenomas. We report a patient with biochemically documented pituitary-based hypercortisolism who had a clinical and biochemical remission following hypophysectomy. Serial sections of the pituitary tissue removed showed hyperplasia of corticotroph cells but no adenoma. Hypophysectomy was complete as documented by serum levels of FSH, LH, TSH, prolactin, hGH and ACTH at the lower limits of the respective assays, with no response to appropriate stimuli. This case demonstrates that a minority of patients with Cushing's disease has corticotroph cell hyperplasia without a pituitary adenoma.

Regulation of serum spadin propeptide: An antidepressant response probe

2016 ◽  
Vol 33 (S1) ◽  
pp. S417-S417
Author(s):  
J. Mazella ◽  
C. Devader ◽  
M. Roulot ◽  
M. Borsotto ◽  
C. Heurteaux
Keyword(s):  
Serum Level ◽  
Healthy Subjects ◽  
Antidepressant Treatment ◽  
Serum Insulin ◽  
Maximal Activity ◽  
Serum Levels ◽  
Significant Rise ◽  
Detection Range ◽  
Competing Interest ◽  
Depressive Patients

ObjectivesWe previously discovered that spadin, a short analogue of the propeptide (PE) released from the maturation of sortilin, displays potent antidepressant properties. Since the PE level can be measured in the blood, we aimed to investigate how the PE serum concentration is regulated in mice. We wondered whether the PE serum levels vary between healthy subjects and patients with major depressive disorder (MDD).MethodsWe developped a dosing method based on the AlphaScreen™ technology (Perkin) which allow to selectively detect both PE, spadin and metabolic products from these peptides with a detection range of 1 ng/mL.ResultsWe found that insulin significantly up-regulated serum PE concentration from 26.15 ± 2.63 to 41.43 ± 6.27 nM (P = 0.0318). Analysis during circadian cycle in mice revealed that the amount of PE and its derivatives significantly varied during the cycle being higher during the period of maximal activity (dark period). We also measured serum insulin concentration between 1 and 7 pm and observed a significant rise confirming the relationships between insulin and PE concentration. We showed that the serum level of PE is lower in depressive patients than in healthy non-psychiatric. We observed that the weaker level of PE in depressive patients can recover the level of healthy subjects after a chronic antidepressant treatment.ConclusionsDosing the serum level of PE could be a promising approach for the diagnosis of depression and to determine the remission of the disease.Disclosure of interestThe authors have not supplied their declaration of competing interest.

The effect of naloxone on ATCH and β-endorphin in patients with Cushing's disease

1985 ◽  
Vol 110 (2) ◽  
pp. 170-175 ◽  
Author(s):  
B. Baranowska ◽  
W. Dorobek ◽  
W. Misiorowski ◽  
W. Jeske ◽  
M. H. Abdel-Fattah
Keyword(s):  
Cushing’S Disease ◽  
Healthy Subjects ◽  
Opiate Receptor ◽  
Cushing's Disease ◽  
Receptor Blockade ◽  
Acth Secretion ◽  
Endogenous Opiates ◽  
Paradoxical Response ◽  
Cortisol Release ◽  
Serum Acth

Abstract. Endogenous opiates may be important in the control of ACTH secretion in men. The effect of opiate receptor blockade by naloxone on ACTH, β-endorphin-like substance and cortisol release was studied in healthy women and in 9 patients with Cushing's disease. In the healthy subjects, ACTH, β-endorphin and cortisol levels were increased in response to naloxone. However, in 3 our of the 9 patients with Cushing's disease, a paradoxical decrease in serum ACTH, cortisol and β-endorphin concentrations was observed after naloxone administration. In the patients with a paradoxical response to naloxone, transsphenoidal microadenomectomy was ineffective.

Vasoactive intestinal polypeptide enhances ACTH levels in some patients with adrenocorticotropin - secreting pituitary adenomas

1987 ◽  
Vol 116 (2) ◽  
pp. 216-220 ◽  
Author(s):  
Bruno Ambrosi ◽  
Domenico Bochicchio ◽  
Alessandro Sartorio ◽  
Francesco Morabito ◽  
Giovanni Faglia
Keyword(s):  
Vasoactive Intestinal Polypeptide ◽  
Cushing’S Disease ◽  
Normal Subjects ◽  
Significant Rise ◽  
Cushing's Disease ◽  
Plasma Acth ◽  
Nelson’S Syndrome ◽  
Nelson's Syndrome ◽  
Cortisol Levels ◽  
Intestinal Polypeptide

Abstract. Vasoactive intestinal polypeptide (VIP) was administered (75 μg iv over 12 min) to 14 patients with Cushing's disease, 1 patient with Nelson's syndrome, and 8 normal subjects. VIP induced a significant rise of plasma ACTH levels in 6 patients with Cushing's disease, from a baseline of 13.2 pmol/l (9.9–18.5 pmol/l) to a peak of 24.5 pmol/l (7.7–18.9 pmol/l), median and range (P < 0.05), and in the patient with Nelson's syndrome, from a baseline of 260.9 to 461.3 pmol/l. A significant elevation of cortisol levels was also observed, from a baseline of 567 nmol/l (185–842 nmol/l) to a peak of 727 nmol/l (364–1029 nmol/l); P < 0.05. No modifications in plasma ACTH and cortisol levels were noticed in the other 8 patients with Cushing's disease, or in the normal subjects. In the responsive patients, the median plasma ACTH level reached after VIP was found to be less than that induced by CRH administration. In 2 of the responsive patients, VIP was injected again after successful microadenomectomy and did not then cause changes in ACTH and cortisol concentration. These data demonstrate that VIP specifically stimulates ACTH release in some patients with corticotropinomas but not in normal subjects; the disappearance of such abnormal ACTH responses after successful adenomectomy suggests the presence of specific VIP receptors only on the adenomatous corticotropes.

scholarly journals Voxel-based comparison of brain glucose metabolism between patients with Cushing's disease and healthy subjects

2018 ◽  
Vol 17 ◽  
pp. 354-358 ◽  
Author(s):  
Shuai Liu ◽  
Yinyan Wang ◽  
Kaibin Xu ◽  
Fan Ping ◽  
Fang Li ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Cushing’S Disease ◽  
Healthy Subjects ◽  
Cushing's Disease ◽  
Brain Glucose ◽  
Brain Glucose Metabolism

Changes in pituitary secretion induced by an agonist-antagonist opioid drug, buprenorphine

1983 ◽  
Vol 104 (3) ◽  
pp. 257-260 ◽  
Author(s):  
Ermanno Rolandi ◽  
Alessandra Marabini ◽  
Roberto Franceschini ◽  
Valeria Messina ◽  
Patrizia Bongera ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Serum Cortisol ◽  
Serum Levels ◽  
Significant Rise ◽  
The Other ◽  
Opiate Antagonist ◽  
Pituitary Secretion ◽  
Serum Gh ◽  
Opiate Agonist ◽  
Antagonist Effect

Abstract. The im administration in 6 healthy subjects of buprenorphine, a derivative of the morphine alkaloid thebaine with agonist-antagonist properties, resulted in a significant rise of serum Prl within 45–240 min, a small and transient increase in serum GH and a significant fall in serum cortisol values. Conversely, no appreciable changes in the serum levels of the other hormones studied were found. The observed hormonal effects indicate that, in man, buprenorphine exerts an opiate agonist rather than an opiate antagonist effect.

Sign in / Sign up

Export Citation Format

Share Document